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Since the ﬁrst report of catheter ablation curing atrial ﬁbrillation (AF), numerous
techniques have evolved, from linear ablation to segmental pulmonary vein (PV) isolation,
extensive encircling PV isolation, LA linear ablation, ablation of complex fragmented atrial
electrograms (CFAE) and stepwise ablation. We developed a new approach for complete
isolation of the posterior LA including all PVs, namely box isolation. In the posterior LA,
there are many arrhythmogenic substrates for AF, including the triggers, reentries and
ganglionated plexi. Box isolation can contain these abnormal substrates in the posterior LA.
Box isolation is associated with a high clinical success rate in paroxysmal AF. However, in
persistent AF or longstanding persistent AF, only box isolation may not be suﬃcient,
therefore, additional ablation at sites with CFAE outside the box area is needed to improve the
clinical outcome. A hybrid approach of combining box isolation with CFAE ablation is highly
eﬀective in the majority of patients with persistent AF or longstanding persistent AF. Thus,
AF ablation is an eﬀective and safe treatment for AF that oﬀers an excellent chance for a
lasting cure.
(J Arrhythmia 2011; 27: 255–267)
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Introduction
It is well accepted that the development of atrial
ﬁbrillation (AF) requires both a trigger and arrhyth-
mogenic substrate. The goals of ablation are to
prevent AF by either eliminating the trigger that
initiates AF or by altering the substrate. Haissaguerre
et al.1) ﬁrst found that most focal AF is initiated by
premature beats from the oriﬁces of the pulmonary
veins (PVs) or from the myocardial sleeves inside
the PVs, and catheter ablation of triggered foci has
been shown to cure AF. This discovery started a new
era in the treatment of AF. The initial approach was
focal ablation of the culprit PV identiﬁed as the
triggering site initiating AF. However, detecting the
exact focus is often diﬃcult when atrial premature
beats are infrequent, or each extrasystole may induce
AF, thus necessitating repeated deﬁbrillation. For
these reasons, Haissaguerre et al.2) provided an
alternative approach that simply seeks to electrically
isolate the PVs from the left atrium (LA) at
electrophysiological breakthroughs from the LA to
the PV.
Rationale of PV Isolation
A recent consensus of world-renowned experts in
AF ablation states that PV isolation is a cornerstone
of catheter ablation of AF, and most laboratories
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perform PV isolation as the primary approach for
patients with paroxysmal AF. The dominant rotors in
AF are localized primarily at the PV-LA junction, as
demonstrated by several investigators.3–5) Moreover,
vagal inputs may be very important in both trigger-
ing and maintaining AF, and many of these inputs
are clustered close to the PV-LA junction.6) We also
demonstrated that the PV-LA junction has hetero-
geneous electrophysiological properties capable of
sustaining reentry.7) In our study using basket
catheter mapping, unstable reentrant circuits were
observed in response to single extrastimulus and
repetitive focal activities in the PV. These reentrant
circuits were short lived (i.e., were unstable).
Furthermore, a PV-LA reciprocating reentrant circuit
involving the exit breakthrough point and the
entrance breakthrough point at the PV-LA junction
was observed. A wave front from a focal discharge
in the PV goes through the nearest exit breakthrough
point and re-enters to the PV from the entrance site,
forming a reentrant circuit. The diﬀerent conduction
property of the exit and entrance sites depending on
the site of pacing or discharge may contribute to the
reentry formation. Wave fronts traveling to and from
the LA may play an important role in the formation
of unstable reentrant wave fronts. The presence of
anisotropic structures at the PV-LA junction may be
critical to form reentry. Thus, the PVs play a critical
role in both triggering and maintaining AF. There-
fore, the goal of present AF ablation is to electrically
disconnect the PVs from the rest of the atrium by
ablating around the origin of the PVs. The circum-
ferential PV isolation may alter the arrhythmogenic
substrate by elimination of tissue located near the
PV-LA junction that provides a substrate for reen-
trant circuits that may generate or perpetuate AF,
and/or by reduction of the mass of atrial tissue
needed to sustain reentry.
Earlier studies of electrophysiology-guided seg-
mental ablation at the ostial level suggested that
PV disconnection could be achieved with minimal
ablation by targeting speciﬁc ‘‘breakthrough’’ points
between the PV and LA.2,8) Complete electrical
isolation was typically achieved after 50% of
the circumference of the PV ostium was ablated.8)
However, PV ostial ablation may result in PV
stenosis.9,10) Therefore, most operators have moved
toward ablation away from the PV ostium toward the
level of the antrum.11–13) The antrum blends into the
posterior wall of the LA. To encompass as much of
the PV structure as possible, ablation needs to be
performed around the entire antrum, along the
posterior LA wall.13) According to the reports from
several groups using ablation of all 4 PVs outside the
tubular portion, the success rate without anti-
arrhythmic drugs is much more consistent, at 75 to
95%.12,14–18) A further 10 to 20% of patients may
become responsive to previously ineﬀective antiar-
rhythmic drugs.19,20) Some variation remains, partly
because of diﬀerences in the precise end point used
and operator experience.
Advantages of Box Isolation
Both PVs and the posterior LA are developed
from the sinus venosus, where there are many
pacemaker cells with spontaneous rhythmic activity
in the early embryonic heart.21) The discrete site of
high-frequency periodic activity is localized most
often to the posterior LA, including the PV during
AF in sheep hearts.22) Non-PV foci originated mainly
from the PV ostium or from the posterior LA,23) and
the posterior LA and the LA roof serve as a substrate
for maintenance of AF in patients with AF.24,25)
It has been proposed that surgical procedures for
isolating the posterior LA and PVs could cure AF
in 93% of patients with lone AF26) and 86% with
chronic AF.27) These ﬁndings support that isolation
of not only PVs but also the whole posterior LA can
result in a much better cure rate in the patients with
paroxysmal and persistent AF. Therefore, we devel-
oped a new approach for complete isolation of the
posterior LA including all PVs, namely box isolation
(Figure 1).28) In the posterior LA, there are many
arrhythmogenic substrates for AF, including the
ganglionated plexi, reentries and triggers. Box
isolation can contain these abnormal substrates in
the posterior LA. A big diﬀerence between box
isolation and extensive two by two PV isolation is
the line design of the posterior LA. The total length
of two horizontal lines in box isolation is shorter
than two vertical lines in two-by-two continuous
circular lesions (Figure 2). Although the total length
of lines in box isolation is shorter than in extensive
PV isolation, box isolation can isolate the posterior
LA wider than two-by-two continuous circular
lesions (Figure 3). Thus, box isolation can minimize
lesions and maximize the success rate.
Techniques and Endpoints for Box Isolation
We perform box isolation as the primary approach
for patients with all types of AF. Radiofrequency
energy was delivered with a power of 30W using an
irrigated-tip ablation catheter. The temperature was
limited to 40 C. Although only a part of the ﬂoorline
crosses close to the esophagus, the transverse width
of the esophagus in contact with the posterior LA
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may be shorter than its vertical length and therefore
the ﬂoorline would be safer for the esophagus than
the posterior vertical line. However, the operator
should pay attention to ablation of the esophageal
aspect of the ﬂoorline by decreasing the power and
duration of RF energy application. Therefore, we
monitor the luminal esophageal temperature with a
catheter in the esophagus at a position close to the tip
of the ablation catheter. During the ablation at the
posterior LA close to the esophagus, cooling water
through a tube just above the catheter was infused
into the esophagus and the ablation was performed
at a maximum power of 20W and a temperature of
40 C. If the esophageal temperature was higher than
38 C, RF applications were interrupted. Radio-
frequency energy was delivered for 30 seconds at
each point.
Continuous lesions at the anterior portions of the
ipsilateral superior and inferior PVs were initially
created under guidance of double Lasso catheters
and the 3D mapping system. Ablation was started at
the superior wall and continued around the anterior
and inferior venous perimeter. There was no vertical
lesion line created at the posterior portions of the
PVs along the esophageal aspect of the posterior LA.
However, when PVs were not isolated by only
anterior lines, segmental ablation at the breakthrough
points was performed (Figure 4). After complete
isolation of all PVs was created, ablation of the LA
roof was then performed by creating a contiguous
line of ablation lesions joining the superior PVs.
Finally, ablation of the LA ﬂoor was performed by
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Figure 3 Diﬀerence between box isolation and extensive
2-by-2 PV isolation in isolated area
Total isolated area in box isolation (22.1 cm2) is wider than that in
two-by-two PV isolation (17.5 cm2).
Figure 1 Advantages of box isolation
Classical one-by-one PV isolation can be com-
plicated by occurrence of PV stenosis. Two-by-
two PV isolation can decrease the risk of PV
stenosis and improve the success rate, but
esophageal injury is a potential complication.
In contrast, box isolation can decrease the risk
of PV stenosis and esophageal injury, and
increase the success rate.
Figure 2 Diﬀerence between box isolation
and extensive 2-by-2 PV isolation in total
length of lines
The total length of two horizontal lines in box
isolation (84mm) is shorter than two vertical
lines in two-by-two PV isolation (99mm).
LSPV: left superior pulmonary vein, LIPV: left
inferior pulmonary vein, RSPV: right superior
pulmonary vein, RIPV: right inferior pulmonary
vein
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creating a contiguous line of ablation lesions joining
the inferior PVs to isolate the posterior LA.
Entrance block of the box lesion was conﬁrmed by
lack of potentials in the box during AF or sinus
rhythm (Figure 5). Exit block of the box lesion was
conﬁrmed during sinus rhythm. Gaps along the
ablation lines were detected and closed using high
voltage (10V) pace mapping through the ablation
catheter (Figure 6). With lack of LA capture, the line
was considered as complete at this location. In case
LSPV
LSPV
LIPV
LIPV
Figure 4 PV isolation
Left: Tracings of electrograms during ablation. Lasso 1 is positioned in the left superior pulmonary vein (LSPV) and Lasso 2 in the left
inferior pulmonary vein (LIPV). Right: Inner view of left PVs. In this case left PVs were not isolated by only anterior lines. Segmental
ablation of the breakthrough points at the carina created simultaneous isolation of left ipsilateral PVs.
Figure 5 Entrance block of the box lesion
Lasso 1 is positioned in LSPV (yellow) and Lasso 2 is positioned at the posterior wall within the box (green). Ablation of a gap at the mid
ﬂoor line (Lasso #6) created the entrance block of the box lesion during AF.
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of LA capture, a gap was suspected and RF energy
was delivered simultaneously while pacing from the
tip of the ablation catheter. The endpoint of box
isolation was deﬁned as bidirectional conduction
block, that is, both lack of potentials in box and lack
of LA capture. This is important to prevent a
recurrence of gap-related atrial ﬂutter.
Ablation of CFAE
PV isolation or box isolation alone is eﬀective for
treating paroxysmal AF,1,28,29) however, not enough
for cure of persistent AF or longstanding persistent
AF.30,31) To improve the clinical outcome, extensive
ablation, including multiple linear lesions and/or
ablation of complex fractionated atrial electrograms
(CFAE), has been widely adopted, particularly in
patients with persistent AF or longstanding persistent
AF.32–37) Nademanee et al.33) have provided a new
electrogram-guided approach by mapping and tar-
geting areas of CFAE deﬁned as fractionated
electrograms composed of two or more deﬂections
with a mean cycle length 120ms. CFAE may
indicate slow conduction, pivot points of wave
fronts, reentries, drivers, and ganglionated plexi.
They showed that AF was terminated in over 85% of
the patients, and reported that after CFAE ablation,
93% of the patients with paroxysmal AF, 87% of the
patients with persistent AF and 78% of the patients
with longstanding persistent AF were arrhythmia-
free including 11% of the patients taking anti-
arrhythmic drugs.34) However, their results were not
fully reproduced by others. Oral et al.35) performed
ablation of CFAE in patients with chronic AF.
In their study, only 12% of the patients had AF
converted to sinus rhythm during the ablation and
4% converted to atrial ﬂutter. Only 33% of the
patients were in sinus rhythm without antiarrhyth-
mic drugs after a single procedure and 57% of the
patients were in sinus rhythm after a second
procedure. Although it is unclear what underlying
factors may be attributed to the diﬀerences in
outcome between the two studies, several reasons
may explain the diﬀerences, including additional
right atrial ablation, power and duration of RF
energy, and endpoint.
Hybrid Approach of Combining Box Isolation
with CFAE Ablation
In our previous study, with box isolation alone,
73% of the patients with persistent AF and 46% of
the patients with longstanding persistent AF were
arrhythmia-free without antiarrhythmic drugs.29) In
non-capture
capture
LSPV
LIPV
RSPV
RIPV
Figure 6 Exit block of the box lesion
Left: During sinus rhythm, gaps along the ablation lines were detected and closed using high voltage (10V) pace mapping through the
ablation catheter. With lack of LA capture (yellow), the line was considered as complete at this location. In case of LA capture (pink), a
gap was suspected and RF energy was delivered simultaneously while pacing from the tip of the ablation catheter. Right: Ablation at the
site with LA capture was continued until lack of LA capture.
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these successful patients, CFAE ablation was not
necessary even if CFAE was present. In the remain-
ing patients who show recurrence of AF, CFAE
ablation may improve the success rate. However, it
is diﬃcult to identify patients who require additional
CFAE ablation. CFAE are sometimes recorded in
a diﬀuse area and numerous ablation applications
are often necessary to eliminate all CFAE or to
terminate AF. It is also diﬃcult to distinguish culprit
CFAE (e.g. CFAE associated with perpetuating AF)
from bystander CFAE. Although the most robust
endpoint may be termination of AF, this generally
requires very long procedure time.36) Furthermore,
extensive ablation is associated with procedural
complications, proarrhythmia,37) stroke risk, and
compromise of atrial mechanical function.38)
Nademanee et al.34) used intravenous ibutilide to
highlight the CFAE associated with perpetuating AF
after CFAE ablation, if the patient remains in AF
despite elimination of all visible CFAE. They
demonstrated that ablation of CFAE resulted in
termination of AF in 95% of the patients; however,
28% required concomitant ibutilide treatment.34) We
used antiarrhythmic drugs before CFAE ablation in
60 patients, including 38 with longstanding persis-
tent AF and 22 with persistent AF who underwent
box isolation. After box isolation, CFAE maps were
created before and after infusion of a pure Naþ
blocker, pilsicainide (1mg/kg), in 30 patients or
a pure IKr blocker, nifekalant (0.3mg/kg), in 30
patients. Nifekalant had a greater eﬀect on AF
termination than pilsicainide (33% versus 7%).
Both pilsicainide and nifekalant similarly decreased
degree of LA fractionation and reduced CFAE
(Figure 7A). Ablation of CFAE localized by pilsicai-
nide and nifekalant terminated AF in 20% and 27%
of the patients, respectively (Figure 7B–D). Endpoint
of ablation was deﬁned as the elimination of CFAE
or termination of AF. After a single ablation
procedure, 17 patients (28%) had a recurrence of
AF; patients in whom AF was terminated by
minimal CFAE ablation had a lower recurrence rate
than those in whom AF was not terminated despite
extensive CFAE ablation (19% versus 35%). A
second ablation procedure was performed in 14
patients (23%) who showed recurrence of AF. At
17 7 months after the last ablation procedure, 55
patients (92%) were free of AF: 47 (78%) without
antiarrhythmic drugs and 8 (13%) with antiarrhyth-
mic drugs. Our procedure can achieve a success rate
as high as that of CFAE ablation without antiar-
rhythmic drugs.34) Therefore, additional ablation of
CFAE may not be necessary when antiarrhythmic
drugs terminate AF after box isolation, and ablation
of only CFAE localized with antiarrhythmic drugs
may be suﬃcient for clinical eﬃcacy. Thus, a hybrid
approach of box isolation combined with ablation of
CFAE localized with antiarrhythmic drugs is feasible
and eﬀective for decreasing the unnecessary ablation
of bystander CFAE.
Long-term Clinical Outcomes
At our own institution, 513 patients including 353
with paroxysmal AF, 73 with persistent AF (<1
year, mean 5 2 months), and 87 with longstanding
persistent AF (1 year, mean 5 4 years) under-
went box isolation. After box isolation, CFAE
ablation was performed in 34 (47%) patients with
persistent AF, and 70 (80%) patients with long-
standing persistent AF. After a single ablation
procedure, AF recurred in 70 (20%) patients with
paroxysmal AF, 20 (27%) patients with persistent
AF, and 31 (36%) patients with longstanding
persistent AF. In the patients with AF recurrence,
antiarrhythmic drugs were re-administered. A sec-
ond ablation procedure was performed in 39 (11%)
patients with paroxysmal AF, 13 (18%) patients with
persistent AF, and 26 (30%) patients with long-
standing persistent AF, including atrial tachycardia
or ﬂutter in 3% of the patients. During the second
session, recovered conduction gaps along the lines
were found in 88% of the patients and the box
isolation procedure was repeated. Additional abla-
tion was performed in 74% of the patients, including
CFAE in 48% (Figure 8), superior vena cava iso-
lation in 30%, mitral isthmus in 26%, focal atrial
tachycardia in 24%, cavo-tricuspid isthmus in 20%,
and gap related ﬂutter in 11%.
After the follow-up period of 24 8 months,
328 (93%) patients with paroxysmal AF, 65 (89%)
patients with persistent AF and 74 (85%) patients
with longstanding persistent AF were free of AF, of
whom 297 (84%) patients with paroxysmal AF, 58
(79%) patients with persistent AF, and 63 (72%)
patients with longstanding persistent AF were with-
out antiarrhythmic drugs.
Procedure Complications
Cardiac tamponade occurred in 5 patients (1.0%).
This was managed by percutaneous drainage. One
patient had homonymous hemianopsia. One patient
had phrenic nerve injury, but recovered fully within
three months. One patient had gastric hypomotility,
but recovered fully within two weeks. No atrio-
esophageal ﬁstula, signiﬁcant PV stenosis or proce-
dure-related death occurred.
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Conclusions
AF is an arrhythmia associated with increased
morbidity and mortality. Current therapies, especial-
ly antiarrhythmic drugs, not only are ineﬀective but
also present a threat to patient quality of life and
even longevity. AF ablation is an eﬀective, safe, and
established treatment for AF that oﬀers an excellent
chance for a lasting cure. Therefore, it is about time
that AF ablation could be considered a ﬁrst-line
therapy for selected patients with AF in terms of
eﬃcacy and safety when performed by experienced
operators. AF ablation requires operator skill in
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Figure 7 Termination of AF by the ablation of localized CFAE with pilsicainide
A: Regional distribution of CFAE in the LA before and after pilsicainide and the corresponding bipolar electrograms during AF. CFAE
mapping revealed multiple CFAE sites (white color), including the LA septum, LA anterior wall, and near the mitral annulus region.
Before pilsicainide, both sites A and B showed CFAE, but after pilsicainide only site B still showed CFAE. B: Ablation of localized CFAE
with pilsicainide. A Lasso catheter was positioned in the LA appendage. Ablation (#7) of CFAE at the LA appendage was performed.
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CD
Figure 7 Termination of AF by the ablation of localized CFAE with pilsicainide
C: Ablation (#10) of the CFAE at the LA appendage was performed. D: Ablation (#10) of the last CFAE at the LA appendage resulted in
the restoration of sinus rhythm.
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Figure 8 Ablation of CFAE during second session
Tracings of electrograms during second session in a patient with longstanding persistent AF. A Lasso catheter was positioned in the left
atrial appendage. During second session, complete box isolation had been created, ablation of CFAE was then performed. A: CFAE was
observed at the mitral annulus (red square). Mean AF cycle length of coronary sinus was 128msec. B: Ablation of CFAE at the mitral
annulus eliminated all CFAE in the LA and prolonged AF cycle length from 128 to 143msec.
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Lateral RA
RAA
ATAF
Figure 8 Ablation of CFAE during second session
C: CFAE in the RA was then mapped. Severe CFAE were observed in the right atrial appendage (RAA). AF cycle length at the high RA
(HRA) was shorter than that at the coronary sinus (CS) or left atrial appendage. D: Ablation of CFAE in the RA converted AF to atrial
tachycardia (AT) with a cycle length of 248msec.
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manipulating catheters, understanding all facets of
clinical electrophysiology, and treating procedure-
related complications.
The present reality will gradually develop, and
advances such as robotically controlled catheters
will help electrophysiologists to become more
proﬁcient to the task. AF ablation should be
performed in centers that are well-equipped with
an advanced mapping system and an experienced
team to achieve excellent outcomes.
432
E
F
Posterior RA
1
Figure 8 Ablation of CFAE during second session
E: The mechanism of AT was focal AT originated from the posterior RA. F: Ablation of the focus terminated AT.
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